Pharmacokinetics and pharmacodynamics of propofol in cancer patients undergoing major lung surgery
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 605534225 | ||
| 003 | CHVBK | ||
| 005 | 20210128100841.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 210128e20150401xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1007/s10928-015-9404-6 |2 doi |
| 035 | |a (NATIONALLICENCE)springer-10.1007/s10928-015-9404-6 | ||
| 245 | 0 | 0 | |a Pharmacokinetics and pharmacodynamics of propofol in cancer patients undergoing major lung surgery |h [Elektronische Daten] |c [Krzysztof Przybyłowski, Joanna Tyczka, Damian Szczesny, Agnieszka Bienert, Paweł Wiczling, Katarzyna Kut, Emilia Plenzler, Roman Kaliszan, Edmund Grześkowiak] |
| 520 | 3 | |a Despite the growing number of cancer cases and cancer surgeries around the world, the pharmacokinetics (PK) and pharmacodynamics (PD) of anesthetics used in this population are poorly understood. Patients operated due to cancer are usually in severe state and often require chemotherapy. It might affect the PK/PD of drugs used in this population. Therefore,inthisstudy we explored the PK/PD of propofol in cancer patients having a major lung surgery. 23 patients that underwent a propofol-fentanyl total intravenous anesthesia were included in the analysis. A large set of demographic, biochemical and hemodynamic parameters was collected for the purpose of covariate analysis. Nonlinear mixed effect modeling in NONMEM was used to analyze the collected data. A three-compartment model was sufficient to describe PK of propofol. The anesthetic effect (AAI index) was linked to the propofol effect site concentrations through a sigmoidal E max model. A slightly higher value of clearance, a lower value of distribution clearance, and a decreased volume of peripheral compartment were observed in our patients, as compared with the literature values reported for healthy volunteers by Schnider et al. and by Eleveld et al. Despite these differences, both models led to a clinically insignificant bias of −8 and −1% in concentration predictions, as reflected by the median performance error. The C e50 and propofol biophase concentration at the time of postoperative orientation were low and equaled 1.40 and 1.13mg/L. The population PK/PD model was proposed for cancer patients undergoing a major lung surgery. The large body of studied covariates did not affect PK/PD of propofol significantly. The modification of propofol dosage in the group of patients under study is not necessary when TCI-guided administration of propofol by means of the Schnider model is used. | |
| 540 | |a The Author(s), 2015 | ||
| 690 | 7 | |a Propofol |2 nationallicence | |
| 690 | 7 | |a PK/PD |2 nationallicence | |
| 690 | 7 | |a AAI index |2 nationallicence | |
| 690 | 7 | |a Cancer patients |2 nationallicence | |
| 690 | 7 | |a Major lung surgery |2 nationallicence | |
| 700 | 1 | |a Przybyłowski |D Krzysztof |u Department of Clinical Pharmacy and Biopharmacy, Karol Marcinkowski University of Medical Sciences, Poznan, Poland |4 aut | |
| 700 | 1 | |a Tyczka |D Joanna |u Intensive Care Department, Pulmonary Diseases and Thoracic Surgery Center, Poznan, Poland |4 aut | |
| 700 | 1 | |a Szczesny |D Damian |u Department of Biopharmaceutics and Pharmacokinetics, Medical University of Gdansk, Al. Gen. J. Hallera 107, 80-416, Gdańsk, Poland |4 aut | |
| 700 | 1 | |a Bienert |D Agnieszka |u Department of Clinical Pharmacy and Biopharmacy, Karol Marcinkowski University of Medical Sciences, Poznan, Poland |4 aut | |
| 700 | 1 | |a Wiczling |D Paweł |u Department of Biopharmaceutics and Pharmacokinetics, Medical University of Gdansk, Al. Gen. J. Hallera 107, 80-416, Gdańsk, Poland |4 aut | |
| 700 | 1 | |a Kut |D Katarzyna |u Department of Clinical Pharmacy and Biopharmacy, Karol Marcinkowski University of Medical Sciences, Poznan, Poland |4 aut | |
| 700 | 1 | |a Plenzler |D Emilia |u Department of Clinical Pharmacy and Biopharmacy, Karol Marcinkowski University of Medical Sciences, Poznan, Poland |4 aut | |
| 700 | 1 | |a Kaliszan |D Roman |u Department of Biopharmaceutics and Pharmacokinetics, Medical University of Gdansk, Al. Gen. J. Hallera 107, 80-416, Gdańsk, Poland |4 aut | |
| 700 | 1 | |a Grześkowiak |D Edmund |u Department of Clinical Pharmacy and Biopharmacy, Karol Marcinkowski University of Medical Sciences, Poznan, Poland |4 aut | |
| 773 | 0 | |t Journal of Pharmacokinetics and Pharmacodynamics |d Springer US; http://www.springer-ny.com |g 42/2(2015-04-01), 111-122 |x 1567-567X |q 42:2<111 |1 2015 |2 42 |o 10928 | |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s10928-015-9404-6 |q text/html |z Onlinezugriff via DOI |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 900 | 7 | |a Metadata rights reserved |b Springer special CC-BY-NC licence |2 nationallicence | |
| 908 | |D 1 |a research-article |2 jats | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-springer | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1007/s10928-015-9404-6 |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Przybyłowski |D Krzysztof |u Department of Clinical Pharmacy and Biopharmacy, Karol Marcinkowski University of Medical Sciences, Poznan, Poland |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Tyczka |D Joanna |u Intensive Care Department, Pulmonary Diseases and Thoracic Surgery Center, Poznan, Poland |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Szczesny |D Damian |u Department of Biopharmaceutics and Pharmacokinetics, Medical University of Gdansk, Al. Gen. J. Hallera 107, 80-416, Gdańsk, Poland |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Bienert |D Agnieszka |u Department of Clinical Pharmacy and Biopharmacy, Karol Marcinkowski University of Medical Sciences, Poznan, Poland |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Wiczling |D Paweł |u Department of Biopharmaceutics and Pharmacokinetics, Medical University of Gdansk, Al. Gen. J. Hallera 107, 80-416, Gdańsk, Poland |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Kut |D Katarzyna |u Department of Clinical Pharmacy and Biopharmacy, Karol Marcinkowski University of Medical Sciences, Poznan, Poland |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Plenzler |D Emilia |u Department of Clinical Pharmacy and Biopharmacy, Karol Marcinkowski University of Medical Sciences, Poznan, Poland |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Kaliszan |D Roman |u Department of Biopharmaceutics and Pharmacokinetics, Medical University of Gdansk, Al. Gen. J. Hallera 107, 80-416, Gdańsk, Poland |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Grześkowiak |D Edmund |u Department of Clinical Pharmacy and Biopharmacy, Karol Marcinkowski University of Medical Sciences, Poznan, Poland |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t Journal of Pharmacokinetics and Pharmacodynamics |d Springer US; http://www.springer-ny.com |g 42/2(2015-04-01), 111-122 |x 1567-567X |q 42:2<111 |1 2015 |2 42 |o 10928 | ||